Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system
Yan Chun Li, … , Shu Q. Liu, Li-Ping Cao
Yan Chun Li, … , Shu Q. Liu, Li-Ping Cao
Published July 15, 2002
Citation Information: J Clin Invest. 2002;110(2):229-238. https://doi.org/10.1172/JCI15219.
View: Text | PDF
Article

1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system

  • Text
  • PDF
Abstract

Research Article

Authors

Yan Chun Li, Juan Kong, Minjie Wei, Zhou-Feng Chen, Shu Q. Liu, Li-Ping Cao

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Effect of VDR inactivation on blood pressure and heart weight/body weigh...
Effect of VDR inactivation on blood pressure and heart weight/body weight ratio. (a) Systolic and diastolic blood pressures of wild-type (white bars) and VDR–/– (black bars) mice. *P < 0.01 vs. corresponding wild-type mice; n = 9 for wild-type mice; n = 8 for VDR–/– mice. (b) Ratio of heart weight to body weight of wild-type and VDR–/– mice. *P < 0.05 vs. wild-type mice; n = 9 in each genotype. (c) Mean blood pressure (BP) of wild-type (white bars) and VDR–/– (black bars) mice untreated or treated with captopril for 5 days. *P < 0.05 vs. corresponding untreated wild-type mice; n = 4 in each genotype in each group.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts